Coldstream Capital Management Inc Taysha Gene Therapies, Inc. Transaction History
Coldstream Capital Management Inc
- $4.64 Billion
- Q1 2025
A detailed history of Coldstream Capital Management Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Coldstream Capital Management Inc holds 207 shares of TSHA stock, worth $465. This represents 0.0% of its overall portfolio holdings.
Number of Shares
207Holding current value
$465% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TSHA
# of Institutions
129Shares Held
147MCall Options Held
66.3KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$45 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$42.3 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$37.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$26.4 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$24.5 Million0.3% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $109M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...